Singapore, Aug. 7 -- XtalPi, a China-based technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, has announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer D.Gregory Verdine. The collaboration, worth up to$5.99 billion, represents one of the largest commitments to date for AI- and robotics-driven pharmaceutical R&D.

Under the agreement, DoveTree gains exclusive global rights to develop and commercialise a portfolio of innovative therapeutics generated through the partnership.

XtalPi has received an upfront payment of$51 millionand is eligible for$49 millionin additional near-term payments, plus developm...